Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1) - Top-Institutions - MDSpire

Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1)

  • By

  • Yoshio Nakamura

  • Naoya Yamazaki

  • Kenjiro Namikawa

  • Hiroshi Uchi

  • Shoichiro Mori

  • Mariko Ogawa-Momohara

  • Taku Fujimura

  • Tatsuya Takenouchi

  • Mana Kurimoto

  • Yuki Yamamoto

  • Atsushi Otsuka

  • Kenji Kabashima

  • Takayuki Fusumae

  • Ikuko Hirai

  • Keiji Tanese

  • Yasuko Saito

  • Masayuki Amagai

  • Ryo Takemura

  • Yasunori Sato

  • Takeru Funakoshi

  • March 4, 2026

  • 0 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Dermato-Oncology
    • Immunotherapy
    • Clinical Trials

  • #2

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Dermato-Oncology
    • Immunotherapy
    • Translational Research

  • #3

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Medical Oncology
    • Immunotherapy
    • Skin Cancer Research

  • #4

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Dermato-Oncology
    • Immunotherapy
    • Clinical Trials

  • #5

    National Cancer Center Hospital
    National Cancer Center Hospital

    Tokyo, Tokyo Prefecture

    Key Differentiators

    • Dermato-Oncology
    • Clinical Trials
    • Immunotherapy

Original Source(s)

Nivolumab in the Treatment of Unresectable Cutaneous Epithelial Cancers: Results from a Phase II Open-Label, Single-Arm Multicenter Trial (NMSC-PD1)

  • by Yoshio Nakamura, Naoya Yamazaki, Kenjiro Namikawa, Hiroshi Uchi, Shoichiro Mori, Mariko Ogawa-Momohara, Taku Fujimura, Tatsuya Takenouchi, Mana Kurimoto, Yuki Yamamoto, Atsushi Otsuka, Kenji Kabashima, Takayuki Fusumae, Ikuko Hirai, Keiji Tanese, Yasuko Saito, Masayuki Amagai, Ryo Takemura, Yasunori Sato, Takeru Funakoshi

  • March 4, 2026

Related Content

Generalized Granuloma Annulare Associated with Lung Adenocarcinoma: A Case Report

Effects of Kumkumadi Taila on Facial Skin Pigmentation, Redness, and Elasticity: An Exploratory Study with Phytochemical Analysis in Primary Skincare

Dermatologic outcomes associated with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a large-scale target trial emulation